SEC Comment Letter 0000000000-24-012076 to China SXT Pharmaceuticals, Inc. (SXTC) (CIK 0001723980) (SXTC)
China SXT Pharmaceuticals, Inc. (SXTC) (CIK 0001723980)
Date: Oct. 30, 2024 · CIK: 0001723980 · Accession: 0000000000-24-012076
AI Filing Summary & Sentiment
File numbers found in text: 333-282776
Letter
October 30, 2024 Feng Zhou Chief Executive Officer China SXT Pharmaceuticals, Inc. 178 Taidong Rd North, Taizhou Jiangsu, China Re:China SXT Pharmaceuticals, Inc. Registration Statement on Form F-3 Filed October 22, 2024 File No. 333-282776 Dear Feng Zhou: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Joan Wu Esq.
Show Raw Text
October 30, 2024
Feng Zhou
Chief Executive Officer
China SXT Pharmaceuticals, Inc.
178 Taidong Rd North, Taizhou
Jiangsu, China
Re:China SXT Pharmaceuticals, Inc.
Registration Statement on Form F-3
Filed October 22, 2024
File No. 333-282776
Dear Feng Zhou:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Joan Wu Esq.